Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy - Full Text View

Purpose

Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy.

Condition	Intervention	Phase
Neoplasms, Prostate	Drug: dutasteride Drug: placebo Drug: bicalutamide	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment
Official Title:	A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase

Resource links provided by NLM:

Genetics Home Reference related topics: prostate cancer

MedlinePlus related topics: Prostate Cancer

Drug Information available for: Bicalutamide Dutasteride

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Time to Disease Progression [ Time Frame: Interval of time between the date of the start of treatment and the date of disease progression (up to Study Month 42) ]
Time to disease progression (PD) is defined as the interval of time between the date of the start of treatment and the date of PD. PD is defined as prostate specific antigen (PSA) progression from Baseline (PSA value is 25% and at least 2 nanograms per milliliter [ng/mL] above Baseline, confirmed by a second PSA value); PSA progression from nadir, without a 50% decrease from Baseline (PSA value is 25% and at least 2 ng/mL above nadir, confirmed by a second PSA value); PSA progression from nadir, with a 50% or more decrease from Baseline (PSA value is 50% and at least 2 ng/mL above nadir, confirmed by a second PSA value); metastatic disease (radiographic evidence of metastatic disease); death due to prostate cancer; or the receipt of post-Baseline rescue medication. PSA confirmation was not required if no subsequent PSA values were available. Participants who did not experience an event were censored at the date of the latest follow-up information.

Secondary Outcome Measures:

Time to Treatment Failure [ Time Frame: Interval of time between the date of the start of treatment and the date of treatment failure (up to Study Month 42) ]
Time to treatment failure is defined as the interval of time between the date of the start of treatment and the date of treatment failure. Treatment failure is defined as PSA progression from Baseline (PSA value is 25% and at least 2 ng/mL above Baseline, confirmed by a second PSA value); metastatic disease (radiographic evidence of metastatic disease); death due to prostate cancer; or receipt of post-baseline rescue medications. PSA confirmation was not required if no subsequent PSA values were available. Participants who did not experience an event were censored at the date of the latest follow-up information.
Number of Participants With PSA Response [ Time Frame: Time from Baseline PSA measurement until the first PSA measurement with a 50% or greater reduction in PSA values (up to Study Month 42) ]
PSA response is defined as a 50% or greater decrease in PSA from Baseline, confirmed by a second PSA measurement. The time of this response was the date of the first PSA measurement that showed a 50% or greater decrease from the Baseline PSA measurement. PSA confirmation was not required if no subsequent PSA values were available.
Change From Baseline in Total PSA at Months 6, 12, 18, 21, and 42 [ Time Frame: Baseline and Months 6, 12, 18, 21, and 42 ]
Change from Baseline in total PSA was measured at each scheduled post-baseline visit using a general linear model with effects for treatment and Baseline total PSA. Analysis was done using the last observation carried forward (LOCF) approach, in which missing post-Baseline values were imputed with earlier non-missing values. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Number of Participants With Metastatic Disease [ Time Frame: Interval of time between the date of the start of treatment and the date of radiographic evidence of metastatic disease (up to Study Month 42) ]
Metastatic disease is that evidenced by a radiographic assessment. The time of metastatic disease was the date of radiographic evidence.


Enrollment:	127
Study Start Date:	May 2007
Study Completion Date:	February 2013
Primary Completion Date:	February 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Arm 1 50 mg bicalutamide and 3.5 mg Dutasteride (IP)	Drug: dutasteride 0.5mg dutasteride (Investigation Product) Drug: bicalutamide 50 mg Casodex or generic equivalent
Placebo Comparator: Arm 2 50 mg bicalutamide and placebo	Drug: placebo making placebo Drug: bicalutamide 50 mg Casodex or generic equivalent

Eligibility


Ages Eligible for Study:	40 Years to 90 Years (Adult, Senior)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Men ≥40 and ≤90 years of age
Must have asymptomatic prostate cancer that has progressed during androgen deprivation therapy (rising PSA). PSA progression must have occurred after first-line treatment with GnRH analogues ( e.g. leuprolide, goserelin) or orchiectomy. PSA progression is defined by three rises in PSA each measured at least 4 weeks apart within the previous year.
Serum PSA ≥2 and ≤20ng/ml from central laboratory. One PSA retest from central laboratory is allowed if the value is <2 or >20ng/ml; or if the PSA value is not consistent with the previous rising PSA values that determined progression while on a GnRH analogue.
Serum Testosterone <50ng/ml from central laboratory.
Non-metastatic prostate cancer as confirmed on prior bone scan performed within 8 weeks of screening.
Expected survival ≥ 2 years
ECOG Performance status 0, 1, or 2

Exclusion criteria:

Additional hormonal therapy (excluding the current use of a GnRH analogue) within the past 6 months of:
Estrogens (e.g. megestrol, medroxyprogesterone, cyproterone, DES)
Drugs with antiandrogenic properties (e.g., spironolactone if >50mg/day, flutamide, bicalutamide*, ketoconazole**, progestational agents)

*The use of an antiandrogen during GnRH analogue induction for <6 weeks is acceptable, but none within the 3 months prior to study entry.

**The use of topical ketoconazole is permitted prior to and during the study. NOTE: Use of dietary and herbal supplements (e.g., selenium, Vitamin E, saw palmetto), excluding daily vitamins, during the study is discouraged, but not prohibited. All dietary and herbal supplement usage will be recorded in the eCRF.
Treatment with oral glucocorticoids during the 3 months prior to randomization or expectation of their use during the study.
Prior chemotherapy for prostate cancer. (prior prostatectomy or radiotherapy to the prostate are allowed)
Prostate surgery including TUNA, TURP, TUIP, laser treatment, thermotherapy, balloon dilatation, prosthesis, and cryosurgical ablation within 2 months prior to enrollment.
Current and/or previous use of the following medications:
Finasteride (Proscar, Propecia), or Dutasteride (GI198745, AVODART) exposure within 6 months prior to study entry
Anabolic steroids (within 6 months prior to study entry)
Participation in any investigational or marketed drug trial within the 30 days prior to the first dose of study drug or anytime during the study period.
Any unstable serious co-existing medical condition(s) including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes; or peptic ulcer disease which is uncontrolled by medical management.
Abnormal liver function test greater than 1.5 times the upper limit of normal for alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase [ALP] or bilirubin.
Serum creatinine >2.0 times the upper limit of normal.
History of another malignancy within five years that could affect the treatment of prostate cancer or survival of the subject.
History or current evidence of drug or alcohol abuse within the last 12 months.
History of any illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject.
Known hypersensitivity to any 5 alpha-reductase inhibitor or to any drug chemically related to dutasteride.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00470834

Show 62 Study Locations

Sponsors and Collaborators

GlaxoSmithKline

Investigators


Study Director:	GSK Clinical Trials	GlaxoSmithKline

More Information

Additional Information:

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. This link exits the ClinicalTrials.gov site